Press Release: InterveXion : InterveXion Therapeutics Receives Japanese Patent for IXT-m200 (Anti-Methamphetamine Antibody)
LITTLE ROCK, ARKANSAS, USA, August 12, 2019 /EINPresswire.com/ -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing immunotherapies for substance abuse disorders, today announced the expansion of its international ...
Read full article »
InterveXion is an Arkansas-based biopharmaceutical company that develops and commercializes novel products for the treatment of addiction disorders.
Read more